Table 1.

Baseline study patient parameters

Characteristic
Female sex — no. (%)	27 (100)
Age — year
Median	65
Range	27–80
Race — no. (%)*
White	22 (81)
Black or African ancestry	3 (11)
Hispanic	2 (7)
GOG performance status — no. (%)†
0	19 (70)
1	5 (19)
2	3 (11)
No. of metastases to be treated by radiosurgery — no. (%)
1	7 (26)
2	8 (30)
3	10 (37)
4	2 (7)
≥ 4	0 (0)
Histopathology — no. (%)
Cervix/vagina squamous cell carcinoma	4 (15)
Endometrial adenocarcinoma	7 (26)
Ovarian adenocarcinoma	15 (56)
Vulvar squamous cell carcinoma	1 (4)
Prior radiation — no. (%)	13 (48)
Inclusive of radiosurgery sit e	9 (33)
> 5000 cGy delivered pretherapy to radio surgery sit e	6 (22)
Prior chemotherapy — no. (%)	27 (100)
No. of prior courses of chemotherapy for metastases — no. (%)
0	1 (4)
1	17 (63)
2	8 (30)
3	1 (4)
Platinum-containing regimen — no. (%)	27 (100)
Taxane-containing regimen — no. (%)	21 (78)
Anthracycline-containing regimen — no. (%)	6 (22)
Topotecan-containing regimen — no. (%)	3 (11)
Gemcitabine-containing regimen — no. (%)	5 (19)

^*Race was self-reported.

^†The Gynecologic Oncology Group (GOG) performance status reflects individual daily living activities on a scale of 0 (fully active with symptoms) to 5 (dead).